Sample Abstract– Structured Format with Numbered References

P001. Properties of the meeting abstract: Mystery elements explained.

[1]Kong-sang (Jackie) Chan, [1,2]Victoria Von Waltz et al on behalf of the RSMA workgroup

[1]University of Abstraction, Boston, MA, USA; [2]Royal Society of Meeting Abstracts (RSMA), Wan Chai, Hong Kong, PR China.

Background: The Background includes what's already known, what's not known about the subject, and describes the purpose for the presentation and aim of study. Avoid using acronyms and jargon.

Methods: The Method section shows how the study was carried out [1], with sample sizes (and variations), source of samples (if limited or defined by location), any requirements for inclusion, and duration of the study [2]. Generic drug names are preferable when describing dosage (for example, use acetaminophen as opposed to Tylenol, Johnson & Johnson Consumer, Inc., US) [3].

Results: The Results section will have findings and comparisons summarized in complete sentences (see also Table P001-1 or Figure P001-1). The data will be used to define the Conclusion, which may be negative, or may not be significant. If all data can't be shared in the limited space, then deposit data in an open repository.

Conclusion: In addition to briefly summarizing the results, this section may also highlight new or unexpected results and advise on future studies. Statements may only refer to the author conclusions collectively and within a wider perspective rather than offering individual and subjective opinions.

Keywords: optional, consistently applied, relevant short phrases, limit of four.

Clinical Trial Registry: NCT12345678; https://clinicaltrials.gov

Data Deposition: https://dx.doi.org/00.0000/m0.figshare.000000.v1

Disclosures: VVWs employer received a grant from Pharmatown. The authors declared no competing interests.

**Corresponding Author:** Given, middle initial, followed by family name, https://orcid.org/0000-0000-0000-0000

References

1. Author J, et al. *Journal Abbrev* 2018; 63 (suppl 6): 8–160. http://doi.org/00.0000/j.0000-0000.0000.00000.x

2. Author B, et al. *Book Title.* Publisher; 2013: 369–377. http://doi.org/00.0000/b.000000000

3. Program Name. Version XX. Company Name; 2016. Accessible: http://www.includethewebaddress.com

4. ABC Committee. *Guide for Authors*; 2024:1552-1554. https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/preparation/1276

Tab P001-1. Table and caption should be included after references.

SL Treatment *	Percentage	n
Therapy 1	28.4	712
Therapy 2	71.6	2136

* SL = Sour Lemon. Modified with permission from ABC Publisher, copyright 2016 [4].

Fig P001-1. Sour Lemon Treatment.

Blue checkers= Therapy 1 (28.4%); Green stripes = Therapy 2 (71.6%).